Literature DB >> 17079360

Effect of goldenseal (Hydrastis canadensis) and kava kava (Piper methysticum) supplementation on digoxin pharmacokinetics in humans.

Bill J Gurley1, Ashley Swain, Gary W Barone, D Keith Williams, Philip Breen, C Ryan Yates, Leslie B Stuart, Martha A Hubbard, Yudong Tong, Sreekhar Cheboyina.   

Abstract

Phytochemical-mediated modulation of P-glycoprotein (P-gp) and other drug transporters may give rise to many herb-drug interactions. Serial plasma concentration-time profiles of the P-gp substrate, digoxin, were used to determine whether supplementation with goldenseal or kava kava modified P-gp activity in vivo. Twenty healthy volunteers were randomly assigned to receive a standardized goldenseal (3210 mg daily) or kava kava (1227 mg daily) supplement for 14 days, followed by a 30-day washout period. Subjects were also randomized to receive rifampin (600 mg daily, 7 days) and clarithromycin (1000 mg daily, 7 days) as positive controls for P-gp induction and inhibition, respectively. Digoxin (Lanoxin, 0.5 mg) was administered p.o. before and at the end of each supplementation and control period. Serial digoxin plasma concentrations were obtained over 24 h and analyzed by chemiluminescent immunoassay. Comparisons of area under the curve (AUC)((0-3)), AUC((0-24)), C(max,) CL/F, and elimination half-life were used to assess the effects of goldenseal, kava kava, rifampin, and clarithromycin on digoxin pharmacokinetics. Rifampin produced significant reductions (p < 0.01) in AUC((0-3)), AUC((0-24)), CL/F, t(1/2), and C(max), whereas clarithromycin increased these parameters significantly (p < 0.01). With the exception of goldenseal's effect on C(max) (14% increase), no statistically significant effects on digoxin pharmacokinetics were observed following supplementation with either goldenseal or kava kava. When compared with rifampin and clarithromycin, supplementation with these specific formulations of goldenseal or kava kava did not appear to affect digoxin pharmacokinetics, suggesting that these supplements are not potent modulators of P-gp in vivo.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17079360      PMCID: PMC1868501          DOI: 10.1124/dmd.106.012708

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  35 in total

1.  Detection of MDR1 single nucleotide polymorphisms C3435T and G2677T using real-time polymerase chain reaction: MDR1 single nucleotide polymorphism genotyping assay.

Authors:  Pengfei Song; Shen Li; Bernd Meibohm; A Osama Gaber; Marsha R Honaker; Malak Kotb; Charles R Yates
Journal:  AAPS PharmSci       Date:  2002

2.  Isoform selective inhibition and inactivation of human cytochrome P450s by methylenedioxyphenyl compounds.

Authors:  M Nakajima; M Suzuki; R Yamaji; H Takashina; N Shimada; H Yamazaki; T Yokoi
Journal:  Xenobiotica       Date:  1999-12       Impact factor: 1.908

3.  Relationship between the clinical effects of berberine on severe congestive heart failure and its concentration in plasma studied by HPLC.

Authors:  X Zeng; X Zeng
Journal:  Biomed Chromatogr       Date:  1999-11       Impact factor: 1.902

4.  Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study.

Authors:  Xiaochun Wu; Qing Li; Huawen Xin; Airong Yu; Mingyuan Zhong
Journal:  Eur J Clin Pharmacol       Date:  2005-08-26       Impact factor: 2.953

5.  The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin.

Authors:  B Greiner; M Eichelbaum; P Fritz; H P Kreichgauer; O von Richter; J Zundler; H K Kroemer
Journal:  J Clin Invest       Date:  1999-07       Impact factor: 14.808

6.  Effect of P-glycoprotein modulators on the pharmacokinetics of camptothecin using microdialysis.

Authors:  T H Tsai; C H Lee; P H Yeh
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

7.  The involvement of P-glycoprotein in berberine absorption.

Authors:  Guo-yu Pan; Guang-Ji Wang; Xiao-Dong Liu; J Paul Fawcett; Yuan-Yuan Xie
Journal:  Pharmacol Toxicol       Date:  2002-10

8.  Human cytochrome p450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components.

Authors:  Parnali Chatterjee; Michael R Franklin
Journal:  Drug Metab Dispos       Date:  2003-11       Impact factor: 3.922

9.  Interaction study between digoxin and a preparation of hawthorn (Crataegus oxyacantha).

Authors:  Roberta Tankanow; Helen R Tamer; Daniel S Streetman; Scott G Smith; Janice L Welton; Thomas Annesley; Keith D Aaronson; Barry E Bleske
Journal:  J Clin Pharmacol       Date:  2003-06       Impact factor: 3.126

10.  The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo.

Authors:  J Christopher Gorski; Shiew-Mei Huang; Amar Pinto; Mitchell A Hamman; Janna K Hilligoss; Narjis A Zaheer; Mehul Desai; Margaret Miller; Stephen D Hall
Journal:  Clin Pharmacol Ther       Date:  2004-01       Impact factor: 6.875

View more
  16 in total

Review 1.  Drug interactions with herbal medicines.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Clin Pharmacokinet       Date:  2012-02-01       Impact factor: 6.447

Review 2.  Potential Influence of Centrally Acting Herbal Drugs on Transporters at the Blood-Cerebrospinal Fluid Barrier and Blood-Brain Barrier.

Authors:  Lilian W Kibathi; SoHyun Bae; Scott R Penzak; Parag Kumar
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-12       Impact factor: 2.441

Review 3.  Evaluation of in vivo P-glycoprotein phenotyping probes: a need for validation.

Authors:  Joseph D Ma; Shirley M Tsunoda; Joseph S Bertino; Meghana Trivedi; Keola K Beale; Anne N Nafziger
Journal:  Clin Pharmacokinet       Date:  2010-04       Impact factor: 6.447

Review 4.  Gene expression profiling as an initial approach for mechanistic studies of toxicity and tumorigenicity of herbal plants and herbal dietary supplements.

Authors:  Lei Guo; Nan Mei; Qingsu Xia; Tao Chen; Po-Chuen Chan; Peter P Fu
Journal:  J Environ Sci Health C Environ Carcinog Ecotoxicol Rev       Date:  2010-01       Impact factor: 3.781

5.  Ginkgo biloba extract induces gene expression changes in xenobiotics metabolism and the Myc-centered network.

Authors:  Lei Guo; Nan Mei; Wayne Liao; Po-Chuen Chan; Peter P Fu
Journal:  OMICS       Date:  2010-02

6.  Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects.

Authors:  Vijay V Upreti; David W Boulton; Li Li; Agatha Ching; Hong Su; Frank P Lacreta; Chirag G Patel
Journal:  Br J Clin Pharmacol       Date:  2011-07       Impact factor: 4.335

7.  Gene expression profiling in male B6C3F1 mouse livers exposed to kava identifies--changes in drug metabolizing genes and potential mechanisms linked to kava toxicity.

Authors:  Lei Guo; Qiang Shi; Stacey Dial; Qingsu Xia; Nan Mei; Quan-zhen Li; Po-Chuen Chan; Peter Fu
Journal:  Food Chem Toxicol       Date:  2009-12-03       Impact factor: 6.023

Review 8.  Interactions between herbal medicines and prescribed drugs: an updated systematic review.

Authors:  Angelo A Izzo; Edzard Ernst
Journal:  Drugs       Date:  2009       Impact factor: 9.546

9.  Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics.

Authors:  Bill J Gurley; Ashley Swain; D Keith Williams; Gary Barone; Sunil K Battu
Journal:  Mol Nutr Food Res       Date:  2008-07       Impact factor: 5.914

10.  Analysis of gene expression changes of drug metabolizing enzymes in the livers of F344 rats following oral treatment with kava extract.

Authors:  Lei Guo; Quanzhen Li; Qingsu Xia; Stacey Dial; Po-Chuen Chan; Peter Fu
Journal:  Food Chem Toxicol       Date:  2008-12-07       Impact factor: 6.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.